Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
Beijing Northland Biotech. Co., Ltd. · Acute Myocardial Infarction (AMI) · Acute Myocardial Infarction of Anterior Wall
Phase 2
Not yet recruiting
189
2026-05
Evidence dashboardStudies since 2006Updated Jul 31, 2026
Thymosin Beta-4Clinical Trials.
A source-linked view of every Thymosin Beta-4 study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 18
- Recruiting
- 2
- Completed
- 11
- Terminated
- 2
- Results posted
- 7
- Average enrollment
- 137
- Countries
- 5
- Highest phase
- Phase 3
Largest indexed study
700 participants · NCT03937882 →Developer / research origin
RegeneRx
Evidence summary
Activity is not efficacy.
Thymosin Beta-4 appears in 18 indexed studies: 2 recruiting, 11 completed and 7 with registry results posted. The highest registered development stage in this snapshot is Phase 3. These counts measure registry activity; they do not establish that Thymosin Beta-4 is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
Hudson Biotech · Atherosclerotic Cardiovascular Diseases · Endothelial Dysfunction
Phase 1 / Phase 2
Recruiting
80
2026-03
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
ReGenTree, LLC · Neurotrophic Keratopathy
Phase 3
Recruiting
70
2025-12
NCT IDStudyPhase / statusEnrollmentUpdated
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction
Beijing Northland Biotech. Co., Ltd. · Acute Myocardial Infarction
Phase 2
Completed
90
2024-06
Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction
Beijing Northland Biotech. Co., Ltd. · Acute Myocardial Infarction
Phase 2
Completed
62
2022-08
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
ReGenTree, LLC · Dry Eye Syndromes · Dry Eye
Phase 3
Completed
700
2022-05
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
ReGenTree, LLC · Dry Eye Syndrome
Phase 3
Completed
601
2022-01
A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers
Beijing Northland Biotech. Co., Ltd. · Healthy
Phase 1
Completed
54
2020-09
A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers
Beijing Northland Biotech. Co., Ltd. · Healthy
Phase 1
Completed
30
2020-09
Showing 6 of 11 studies
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction
RegeneRx Biopharmaceuticals, Inc. · Acute Myocardial Infarction · ST Elevation Myocardial Infarction
Phase 2
Withdrawn
0
2021-09
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers
RegeneRx Biopharmaceuticals, Inc. · Myocardial Infarction · Myocardial Ischemia
Phase 1
Withdrawn
0
2017-04
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds
ReGenTree, LLC · Diabetes
Phase 2
Terminated
12
2015-07
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
RegeneRx Biopharmaceuticals, Inc. · Epidermolysis Bullosa
Phase 2
Terminated
30
2014-05
Full study index
Search Thymosin Beta-4 trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
18 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 20937304 ↗Limana F, Capogrossi MC, Germani A. The epicardium in cardiac repair: from the stem cell view. Pharmacol Ther. 2011 Jan;129(1):82-96. doi: 10.1016/j.pharmthera.2010.09.002. Epub 2010 Oct 19.Linked from NCT05485818PMID 21952932 ↗Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail. 2011 Nov;13(11):1161-71. doi: 10.1093/eurjhf/hfr122. Epub 2011 Sep 27.Linked from NCT05485818PMID 18537603 ↗Gutierrez SH, Kuri MR, del Castillo ER. Cardiac role of the transcription factor NF-kappaB. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):153-60. doi: 10.2174/187152908784533702.Linked from NCT05485818PMID 21527742 ↗Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res. 2011 Apr 29;108(9):1122-32. doi: 10.1161/CIRCRESAHA.110.226928.Linked from NCT05485818PMID 23050819 ↗Srivastava D, Ieda M, Fu J, Qian L. Cardiac repair with thymosin beta4 and cardiac reprogramming factors. Ann N Y Acad Sci. 2012 Oct;1270:66-72. doi: 10.1111/j.1749-6632.2012.06696.x.Linked from NCT05485818PMID 22236126 ↗Dube KN, Bollini S, Smart N, Riley PR. Thymosin beta4 protein therapy for cardiac repair. Curr Pharm Des. 2012;18(6):799-806. doi: 10.2174/138161212799277699.Linked from NCT05485818PMID 25826322 ↗Sosne G, Dunn SP, Kim C. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 May;34(5):491-6. doi: 10.1097/ICO.0000000000000379.Linked from NCT01393132
Related pages
Keep researching Thymosin Beta-4.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.